KDC-MN-345 – Kodiac biolabs

Plain-language summaryIntrigue 54 / 100

Etomidate is an intravenous induction anesthetic used when cardiovascular stability matters most, such as in trauma patients with low blood pressure or those with significant heart disease. It enhances GABA-A signaling at a different site than propofol and produces minimal blood pressure or heart rate changes. The major liability is adrenocortical suppression: etomidate inhibits the 11-beta-hydroxylase enzyme that synthesizes cortisol, and even a single induction dose meaningfully suppresses cortisol production for up to 24 hours. This has limited its use in septic patients, where adrenal suppression is harmful. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

48/100

Mature IV anesthetic; cardiovascular-stable reference probe with CYP11B1 inhibition as its most interesting research legacy

Look, etomidate is one of those compounds that earns its place in a research library on the strength of what it does, not how exciting it is to talk about. Approved by the FDA as Amidate back in 1972, this imidazole IV anesthetic has been a clinical fixture for over five decades, and the research community has had ample time to pick it apart. Thats actually the problem from a research-novelty standpoint: there’s not much left to discover about the parent compound.

The mechanism is worth understanding even if it isnt surprising. Etomidate acts as a positive allosteric modulator at GABA-A receptors with preferential binding to the beta-2 and beta-3 subunits. That subunit selectivity differentiates it from benzodiazepines, which prefer alpha subunit interfaces, and it’s genuinely useful as a pharmacological probe for dissecting GABA-A subtype contributions to sedation and anesthesia. Work from the Forman group at MGH and others has used etomidate-based analogues to map out the transmembrane binding pocket in real detail. As a molecular tool for that specific question, it holds up.

The more compelling research angle, honestly, is the adrenocortical suppression. Etomidate inhibits CYP11B1 (11-beta-hydroxylase), the terminal enzyme in cortisol biosynthesis, with enough potency that a single induction dose suppresses cortisol output for four to six hours. In critically ill ICU patients, this became a serious clinical concern after the Ledingham and Watt findings in the early 1980s, which drove entire analog programs: methoxycarbonyl etomidate, cyclopropyl-MOC-etomidate, and the carboetomidate series are all direct descendants of that liability. Etomidate itself is now the benchmark comparator for studying selective CYP11B1 inhibition, which carries its own therapeutic interest for adrenal excess conditions like Cushing’s syndrome.

What we like: the cardiovascular stability is real and multiply confirmed across decades of clinical use, the beta-subunit-selective GABA-A story has genuine probe value for receptor biology programs, and the CYP11B1 inhibition it revealed spawned research that is arguably more interesting than the compound itself. What we dont like: the parent compound is entirely mature. There is no frontier angle remaining on etomidate proper, and the adrenocortical liability has pushed serious investigators toward next-generation analogs rather than back to the original scaffold.

If your program involves GABA-A subunit pharmacology, CYP11B1 inhibitor screening, or steroidogenesis inhibition analog design, etomidate is a solid reference standard and a logical starting point for comparative work. As a primary research target in 2026, it’s not where you’d put your time. The interesting work is happening in what etomidate spawned, not in the original compound itself.

Novelty: 22
Mechanism promise: 33
In-category differentiation: 48
Evidence quality: 72
Translational signal: 75
Research bench value: 58

Rationale Approved 1972 with a thoroughly characterized mechanism, etomidate scores on evidence and translational signal but loses heavily on novelty and mechanism freshness; its primary research value today is as a reference tool for GABA-A subunit pharmacology and CYP11B1 inhibitor development, not as a primary investigation target.

GABA-A receptor positive allosteric modulator (intravenous anesthetic)

An imidazole intravenous induction anesthetic; cardiovascular stable but causes adrenocortical suppression.

Abstract

Etomidate ((R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; CAS 33125-97-2; molecular formula C14H16N2O2; molecular weight 244.29) is an imidazole intravenous induction anesthetic developed at Janssen and approved by the FDA in 1972 (Amidate). The compound is a GABA-A receptor positive allosteric modulator with a binding site at the beta-2 and beta-3 subunits that produces preferential activity at extrasynaptic and synaptic GABA-A receptors. Distinct among IV anesthetics by minimal cardiovascular effects (preserved blood pressure and heart rate), making it preferred for patients with hemodynamic instability. The principal limitation is dose-dependent inhibition of 11-beta-hydroxylase (CYP11B1), the final enzyme in cortisol biosynthesis; even a single induction dose suppresses cortisol for 4 to 6 hours, with potential clinical consequence in critically ill patients. Plasma half-life is approximately 2 to 5 hours. Used as a reference IV anesthetic with cardiovascular stability and adrenocortical suppression.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-345Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-345

Etomidate

Abstract

Read the full monograph